Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 16, 2023

Efficacy and Safety of CDK4/6 Inhibitors, PI3K/mTOR Inhibitors, and HDAC Inhibitors as Second-Line Treatments for Patients With HR+/HER2− Advanced Breast Cancer

BMC Cancer

 

Additional Info

BMC Cancer
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
BMC Cancer 2023 Aug 29;23(1)805, D Ji, Y Luo, J Wang, S Chen, B Lan, F Ma, B Xu, Y Fan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading